
Prostate Cancer
Latest News

Latest Videos

CME Content
More News

Relugolix was not found to achieve statistical superiority with regard to castration resistance–free survival versus leuprolide acetate in patients with metastatic prostate cancer through 48 weeks.

Patients with prostate cancer who harbor germline BRCA2 mutations were found to have significantly higher rates of somatic BRCA loss, somatic RB1 loss, and MYC amplification compared with non-carriers—factors that were independently associated with poorer survival outcomes.

Ajjai Shivaram Alva, MBBS, discusses the role of PARP inhibitors in prostate cancer, the importance of germline testing, and the need for personalized medicine.

Final data from the pivotal phase 3 ARAMIS trial with darolutamide and androgen deprivation therapy showed that the combination continued to demonstrate a statistically significant improvement in overall survival versus ADT alone in patients with nonmetastatic, castration-resistant prostate cancer.

Daniel P. Petrylak, MD, discusses the pivotal trials that have led to the regulatory approvals of the PARP inhibitors olaparib and rucaparib in patients with metastatic castration-resistant prostate cancer and DNA repair mutations.

Arun Azad, PhD, discusses the results of the post-hoc analyses of the phase 3 ARCHES trial in men with metastatic hormone-sensitive prostate cancer.

Daniel P. Petrylak, MD, discusses the role of prostate-specific antigen screening in prostate cancer.

A new drug application has been submitted to the FDA for TLX591-CDx, a radiopharmaceutical product that targets prostate-specific membrane antigen, for the imaging of prostate cancer through the use of positron emission tomography.

Maha Hussain, MD, FACP, FASCO, discusses the importance of genomic profiling in metastatic castration-resistant prostate cancer.

Paul L. Nguyen, MD, discusses standard and investigational treatment options in high-risk prostate cancer.

Arun Azad, PhD, discusses unmet needs for men with metastatic hormone-sensitive prostate cancer.

With more than 4 years of follow-up, the health-related quality of life of men with nonmetastatic castration-resistant prostate cancer receiving androgen deprivation therapy was shown to be maintained with the addition of apalutamide.

Maha Hussain, MD, FACP, FASCO, discusses the clinical impact of the phase 3 PROfound trial in metastatic castration-resistant prostate cancer.

Paul L. Nguyen, MD, discusses the optimal duration of androgen deprivation therapy in patients with high-risk prostate cancer.

Neal D. Shore, MD, FACS, discusses the objective of the phase 3 HERO trial in advanced prostate cancer.

Atish D. Choudhury, MD, PhD, discusses the goal of treating patients with nonmetastatic castration-resistant prostate cancer.

Continuous administration of the novel tubulin inhibitor VERU-111 proved to be safe and demonstrated antitumor activity, evidenced by prostate-specific antigen reductions, objective tumor responses, and durable activity, in men with previously treated metastatic castration-resistant prostate cancer.

Atish D. Choudhury, MD, PhD, compares the safety profiles of antiandrogen agents in nonmetastatic castration-resistant prostate cancer.

Maha Hussain, MD, FACP, FASCO, discusses the safety profile of olaparib as observed in the phase 3 PROfound trial in men with metastatic castration-resistant prostate cancer.

Quoc-Dien Trinh, MD, discusses the challenges of re-establishing standard surgical procedures in patients with prostate cancer following the initial wave of the coronavirus disease 2019 pandemic.

Quoc-Dien Trinh, MD, discusses the impact of the coronavirus disease 2019 pandemic on prostate cancer.

Atish D. Choudhury, MD, PhD, discusses the different states of nonmetastatic castration-resistant prostate cancer.

Paul L. Nguyen, MD, discusses future research in high-risk prostate cancer.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for olaparib for approval as a monotherapy for metastatic castration-resistant prostate cancer and BRCA1/2 mutations who have progressed after previous therapy with a new hormonal agent.

Treatment with AMG 160 showed a manageable safety profile with preliminary efficacy in patients with metastatic castration-resistant prostate cancer.























































